Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus reported Q2 2026 revenue of $3.0 million, down from the prior year due to the wind-down of the CSL Seqirus collaboration, with a net loss of $23.8 million or $0.84 per share. Pipeline progress remains on track with the ARCT-032 cystic fibrosis Phase 2 study expected to trigger a Phase 3 decision in Q4 2026, supported by a new strategic collaboration with Thermo Fisher for manufacturing and clinical services.
Key figures
- Revenue
- 3000000
- Cash runway
- over two and a half years
- Csl payment
- $12 million
- Net loss 6m
- $50.7 million
- Net loss q2
- $23.8 million
- Cash balance
- $191.5 million
- Csl liability release
- $16 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.